Abstract
The purpose of the study was to provide data on the sources of prostate-specific antigen (Psa) in women, as well as on serum Psa levels in healthy women and in women with benign and malignant breast cancer. Material and methods. We analyzed 50 publications available from PubMed, Medline, Google scholar concerning non-prostatic sources of Psa and its use as a serum tumor-associated marker for benign and malignant breast tumors. Results. In our study, we focus on the recent findings on non-prostatic sources and regulation of Psa synthesis in women as well as on changes in serum concentrations of this marker in patients with benign and malignant breast tumors. Various Psa isoforms (total Psa and free Psa) and free/total ratio for the detection of breast cancer and the assessment of treatment response and early detection of breast cancer recurrence were analyzed. Conclusion . the results obtained highlight the value of the assessment of Psa isoforms for early detection, prediction of therapy response and detection of breast cancer relapse. However, further studies are needed to identify the role of Psa isoforms in the diagnosis and monitoring of breast cancer patients.
Highlights
СИБИРСКИЙ ОНКОЛОГИЧЕСКИЙ ЖУРНАЛ. 2019; 18(6): 96–104 reviews ническом выявлении рецидивов
We focus on the recent findings on non-prostatic sources and regulation of prostate-specific antigen (PSA) synthesis in women as well as on changes in serum concentrations of this marker in patients with benign and malignant breast tumors
Further studies are needed to identify the role of PSA isoforms in the diagnosis and monitoring of breast cancer patients
Summary
СИБИРСКИЙ ОНКОЛОГИЧЕСКИЙ ЖУРНАЛ. 2019; 18(6): 96–104 reviews ническом выявлении рецидивов. P. Dash et al показали, что значения общПСА и свПСА у пациенток с доброкачественными и злокачественными новообразованиями МЖ существенно не различались, но были значительно выше, чем у здоровых женщин [42]. Чувствительность общПСА и свПСА среди больных ДЗМЖ составила 86 % и 28 %, при РМЖ – 70 и 38 % соответственно.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.